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Abstract
Background Anogenital warts (AGW) can cause economic burden on healthcare systems and are associated with emo-
tional, psychological and physical issues.
Objective To provide guidance to physicians on the diagnosis and management of AGW.
Methods Fourteen global experts on AGW developed guidance on the diagnosis and management of AGW in an effort to
unify international recommendations. Guidance was developed based on published international and national AGW guideli-
nes and an evaluation of relevant literature published up to August 2016. Authors provided expert opinion based on their
clinical experiences.
Results A checklist for a patient’s initial consultation is provided to help physicians when diagnosing AGW to get the rele-
vant information from the patient in order to manage and treat the AGW effectively. A number of frequently asked questions
are also provided to aid physicians when communicating with patients about AGW. Treatment of AGW should be individu-
alized and selected based on the number, size, morphology, location, and keratinization of warts, and whether they are
new or recurrent. Different techniques can be used to treat AGW including ablation, immunotherapy and other topical thera-
pies. Combinations of these techniques are thought to be more effective at reducing AGW recurrence than monotherapy. A
simpliﬁed algorithm was created suggesting patients with 1–5 warts should be treated with ablation followed by
immunotherapy. Patients with >5 warts should use immunotherapy for 2 months followed by ablation and a second 2-
month course of immunotherapy. Guidance for daily practice situations and the subsequent action that can be taken, as
well as an algorithm for treatment of large warts, were also created.
Conclusion The guidance provided will help physicians with the diagnosis and management of AGW in order to improve
the health and quality of life of patients with AGW.
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Introduction
Anogenital warts (AGW) are epidermal growth lesions, caused
by the different genotypes of human papillomavirus (HPV),
which occur in the anogenital areas of males and females.1,2
More than 90% of cases of AGW are caused by HPV types 6 and
11.3,4 Usually, HPV is contracted via sexual interactions, while
other potential routes of viral transmission are rare.5 AGW rep-
resent a failure of immune recognition, although they only rarely
have oncogenic potential and are not linked to cervical cancer.6
Although the transmission of HPV does not necessitate clinical
lesions to be present, the viral burden of AGW is usually high
and can therefore facilitate transmission.
Anogenital warts are a cosmetic nuisance and may cause sub-
stantial psychosocial issues for patients,6 as well as creating an
economic burden on healthcare systems. The emotional and psy-
chological issues associated with a diagnosis of AGW can include
shame, embarrassment, anger, depression and guilt.4,7,8 Warts
and the majority of the treatment modalities for the condition
may also cause physical problems such as pain, itching, burning,
irritation, and very rarely, obstruction during childbirth.2,3 In
addition, AGW can impact the sexual activity of patients, either
through fear of transmission or embarrassment of lesions.9 Fur-
thermore, AGW are associated with substantial direct and indi-
rect costs.10 A recent study estimated that the direct cost of
genital wart management in the United Kingdom (UK) in 2012
was £58.44 million.11 The main drivers of cost were disease recur-
rence, the requirement for repeat physician visits and treatment.
The aim of this position statement is to provide guidance for
physicians on the diagnosis and management of AGW in daily
clinical practice. The guidance is intended to supplement, rather
than replace, existing evidence-based treatment guidelines.12–14
Methods
An international panel of 14 global experts on AGW was con-
vened to develop guidance on the diagnosis and management of
AGW in an effort to unify international recommendations.
Guidance was developed based on a review of published interna-
tional and national guidelines on AGW.12–14 A PubMed search
was performed for articles published up to August 2016. Rele-
vant literature on the diagnosis and management of AGW was
evaluated. In situations where insufficient published information
was available, recommendations were developed based on con-
sensus of the authors’ clinical experience. Professor O’Mahony
led communications via email to discuss the development of the
position statement and created the initial draft of the manu-
script. The remaining 13 experts reviewed the manuscript and
provided their input and clinical expertise. The experts provided
all images included in the position statement.
Guidance for the diagnosis of AGW
In terms of diagnosis, the key challenge is ensuring that AGW are
correctly identified. In the first instance, a diagnosis of AGW is usu-
ally made by the patient, which must then be confirmed by clinical
inspection. In the case of uncertain lesions, polymerase chain reac-
tion (PCR) diagnosis of different HPV genotypes can be attempted.
Typical presentations of AGW are shown in Fig. 1. AGW
appear as papillomatous plaques or flat lesions and can be single
Figure 1 Typical presentations of anogenital warts. (a) Acuminate
genital warts: vulval warts, (b) Parafrenular papules with genital wart
on frenulum: normal parafrenular papules together with warts on
the frenulum, (c) Pigmented genital warts: widespread hyperkera-
totic, conﬂuent, pigmented papules of the anogenital region, (d)
Leukoplakic genital warts: ﬂat papules with a white surface over the
foreskin; leucoplakia due to keratinization of mucosa, (e) Scattered
penile genital warts: several lesions over foreskin and scrotum, (f)
Multiple keratotic genital warts: multiple conﬂuent papules of the
vulva and perianal area, (g) Multiple non-keratotic genital warts: typ-
ical localization of genital warts in men, (h) Multiple non-keratotic
genital warts: typical localization of anogenital warts in women.
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or multiple in number. Lesions vary from flesh-coloured to
white, pink or brown.3 They typically manifest in areas of the
body that are in close contact during sex: mainly on the anogeni-
tal areas such as vulva, penis, groin, perineum, perianal skin, but
also in the oral cavity.2 Diagnosis of clinically typical AGW does
not require histological confirmation.
There are many conditions that can be misinterpreted as
AGW (Fig. 2). Differential diagnoses that need to be excluded
include normal skin variations (e.g. pearly penile papules,
parafrenular glands, Fordyce spots, vestibular papillae, sebaceous
cysts), other infectious or inflammatory conditions and other
papules (syphilis on mucosal plates, molluscum contagiosum,
lichen planus, psoriasis, condyloma lata) and benign or malig-
nant neoplastic lesions (papillomatoses of vulva, nevi, verrucous
carcinoma, invasive carcinoma, seborrhoeic keratosis, Bowen’s
disease, Buschke-L€owenstein disease, pigmented or unpig-
mented grade 2–3 intraepithelial neoplasia, lymphangioma).2,3
Pigmented or unusual lesions should be immediately referred to
a specialist.
A checklist for the initial consultation with the patient is
provided in Table 1. This will help physicians when diagnos-
ing AGW to get the relevant information from the patient in
order to manage and treat the AGW effectively. A number of
questions that physicians are frequently asked are shown in
Table 2, along with suggested answers. Patients should be reas-
sured that if they have developed AGW, appropriate treatment
can clear the warts within 3 months.5 Patients should be
informed that AGW are of mostly sexual origin and are
caused by HPV which is contagious; therefore, it is important
for patients to disclose their AGW to recent sexual partners,
who should be advised to visit a physician if they have devel-
oped AGW. Physicians should also inform patients that smok-
ers have a 27% increased risk of developing AGW compared
with non-smokers.15 Furthermore, they should explain that
HPV prevalence in patients who smoke is 48.2% compared
with 37.5% for non-smokers (P < 0.001).16 Generally, warts
develop within weeks or months after acquiring HPV but in a
significant number of cases, the virus can be dormant for
months or years before warts emerge.17
Recommendations when selecting treatment options
Treatment should be individualized for each patient. Although
untreated warts can resolve spontaneously,3,17 most patients
want an immediate intervention to eradicate them. Treatments
need to be selected on the basis of considerations such as the
number, size, morphology, location and keratinization of
warts, and whether they are new or recurrent.8,18 Wart area
should be taken into consideration as one study showed that
AGW with smaller surface areas (2–19 mm2) require signifi-
cantly fewer treatment episodes and take less time to clear
than those with larger surface areas (100–1038 mm2).19
Patient-related considerations also need to be taken into
account such as their preference for home or clinic-based
treatment, and the convenience of the regimen in terms of
dosing frequency and duration.8,18 Patient-applied options are
often preferred as they offer privacy, convenience and auton-
omy.18
Treatment options for AGW are provided in Table 3,20–64
and individual modalities are discussed in more detail below. A
recent meta-analysis of 18 studies of patient-applied therapies
concluded that all are more effective than placebo, although
treatments cannot be ranked in terms of efficacy due to a lack of
head-to-head comparisons.65
Ablative techniques
Ablative techniques are commonly used by physicians to remove
warts in daily practice. However, most are awkward and painful
for the patient. The major frustration is the high rate of recur-
rence with these treatments (see below) and the need for repeat
therapeutic interventions. Ablative techniques are associated
with a risk of bleeding, tissue destruction, slow wound healing
and scarring.44,66
Cryotherapy Cryotherapy is the freezing of AGW using liquid
nitrogen and is often used at a patient’s first clinic visit to
help initiate removal of the AGW. Various handheld devices,
such as Hydrozid (Dunelm Pharmaceuticals, Drogheda, Ire-
land), as well as cryotherapy machines can be used for the
procedure. Hydrozid is a disposable canister, which can be
sprayed accurately onto the wart (Fig. 3). This treatment
option can be repeated weekly, biweekly or every 3 weeks and
is a relatively simple, inexpensive technique, requiring minimal
training. However, it requires many clinic visits and a second
or third cycle of freezing may be needed. Clearance rates of
46–96% have been reported although treatment can cause
pain, necrosis and blistering.45–49,66 For non-Caucasians, post-
inflammatory hypo/hyperpigmentation after treatment with
cryotherapy can be frustrating; therefore, this should be dis-
cussed with patients before proceeding with this treatment
option.
Carbon dioxide and Nd:YAG laser Carbon dioxide (CO2) and
Nd:YAG lasers vaporize lesions using focused infrared light
energy; however, it is not always possible to know the extent of
the infected tissue, and therefore, vaporizing large regions
around the warts is not always feasible. Local anaesthesia is usu-
ally required, especially on extensive and thick lesions as it can
penetrate deeply into the lesions.50
This treatment option is used less frequently than other thera-
pies as it requires specialized and costly equipment, and has an
increased risk of serious complications unless used by an experi-
enced physician.1 However, clearance rates of up to 95% have
been reported in clinical studies, with a head-to-head compar-
ison showing greater efficacy than cryotherapy.47,48,50 It is
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important to note that fumes from laser treatment contain con-
tagious particles and adequate measures should be taken to pre-
vent the virus from spreading. Masks and smoke evacuators
should therefore be used.
Electrocautery Electrocautery uses high-frequency electrical
currents to destroy AGW and requires local anaesthesia and
physician expertise.18,20 Clinical studies have shown clearance
rates of 35–94%.20,49,51 As fumes from electrocautery contain
© 2019 The Authors Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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contagious particles, preventative measures should be put in
place to stop the virus spreading.
Surgery Surgery is performed using scissors or a scalpel and is
particularly suited for removing large lesions causing obstruc-
tion. Local or general anaesthesia is required, and patients may
experience post-operative pain.50 Clearance rates of up to 93%
have been reported in clinical studies.51–53
Trichloroacetic acid (TCA; 33–50%) Physician-applied acidic
treatment causes a chemical burn that destroys the AGW. The
acid can be administered up to three times per week until the
warts have cleared. This process requires a skilled professional to
choose the appropriate lesion and duration of application but it
is easy to apply and effective for treating AGW, with clearance
rates of 70–100% reported in clinical studies (Fig. 4). However,
side-effects such as local discomfort, burning and ulceration are
common, hence the need for careful application.45–47,53,55,66
TCA can also be used to treat small lesions; however, it is not
frequently used due to a high recurrence rate and the risk of
side-effects.
Immunotherapies
Immunotherapies use stimulation of the body’s own immune
system to clear infected lesions.
Figure 2 Differential diagnoses (images on the left) of anogenital warts (images on the right). (a) (a1) Pearly penile papules: normal glands on
the corona glandis, (a2) AGW: small cluster of warts on the coronal sulcus, (b) (b1) Parafrenular glands: normal glands on either side of frenu-
lum, (b2) AGW: parafrenular glands with wart on the frenulum, (c) (c1) Fordyce spots: fordyce spots in a male, (c2) AGW: fordyce spots along-
side a wart, (d) (d1) Papillomatoses of vulva: scattered raised glands can be confused with AGW, (d2) AGW: vulval warts – scattered, soft and
ﬂeshy, the vestibular area, (e) (e1) Syphilis on mucosal plates: painless plaque, which suddenly appears on one or more mucosal membranes,
(e2) AGW: penile wart, (f) (f1) Lichen planus: whitish, ﬁne reticulate papules on the glans and corpus, (f2) AGW: white wart patch, (g) (g1) Mol-
luscum contagiosum and (g2) AGW (arrows on image show lesions): both pink dome-shaped papules and warts, (h) (h1) Bowen’s disease:
whitish plaque on labia minora, (h2) AGW: extensive genital warts, (i) (i1) Pigmented intraepithelial neoplasia: pigmented popular strips that
extend to the anogenital area, (i2) AGW: penile pigmented warts, (j) (j1) Vulvar intraepithelial neoplasia: pigmented popular strips that extend
to the anogenital area, (j2) AGW: extensive soft warts and one large keratinized wart, (k) (k1) Invasive carcinoma of the penis: invasive cancer
of the glans of the penis arising from penile intraepithelial neoplasia, (k2) AGW: condylomata acuminata on the urethral mucosa, (l) (l1)
Buschke-L€owenstein: rapid expansion of budding masses that coalesce to form tumours, (l2) AGW: vulval and anal warts.
Table 1 Checklist for initial consultation
Checklist
• Duration of genital warts
• History of genital warts
• Location of other warts: anal and/or oral
• Previous treatment(s) and clinical result(s)
• Patient with steady partner or with several partners
• Smoking status
• Immune suppression status and comorbidities
• Diabetes
• Allergy to anaesthetics
• History of other sexually transmitted infections
AGW, anogenital warts.
Table 2 Frequently asked questions and answers to guide discussion with patients
Questions Answers
How did I get AGW? AGW are caused by HPV.1 Usually, HPV is contracted via sexual interactions: indirect acquisition is rare5
What is the risk of HPV transmission? The risk of HPV transmission is very high (1.6 sexual interactions are enough to get the
infection). The infection is very common and the vast majority of people have the virus during their lifetime
Is there a treatment? Discuss the modalities and the limitations of treatment, explaining this will not eradicate the virus
Does smoking increase my
risk of developing AGW?
Explain that smokers are at an increased risk of developing AGW and therefore, smoking
cessation should be encouraged15
How long will I have AGW for? AGW can recur several times but with appropriate treatment, most warts should clear within 3 months5
Is this the end of my sex life? Reassure the patient that this is not the case
Should I disclose to my current
and previous partner?
It is important to disclose you have AGW to your current partner in order to allow him/her to be checked
Should I always use a condom? Explain that data have shown that increased levels of condom use is associated with increased
clearance of HPV.88 It is therefore advisable to use condoms routinely
What are the risks during pregnancy? AGW can become large during pregnancy5 but will usually disappear within weeks of delivery.
In rare cases, HPV can be transmitted during child birth resulting in recurrent respiratory
papillomatosis in the infant73,78
Will I develop cancer? AGW are not related to cancer. AGW are caused by certain types of HPV, other types of
HPV can cause cancer5
Can AGW spread to other parts of the body? It is very uncommon for AGW to spread to other body locations
AGW, anogenital warts; HPV, human papillomavirus.
© 2019 The Authors Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2019, 33, 1006–1019
1010 O’Mahony et al.
T
ab
le
3
Tr
ea
tm
en
to
p
tio
ns
fo
rA
G
W
Tr
ea
tm
en
t
M
od
e
of
ac
tio
n
S
ch
ed
ul
e
C
le
ar
an
ce
ra
te
(%
)
R
ec
ur
re
nc
e
ra
te
(%
)
A
dv
an
ta
ge
s
D
is
ad
va
nt
ag
es
R
ef
s
A
bl
at
iv
e
te
ch
ni
qu
es
C
ry
ot
he
ra
py
Li
qu
id
ni
tr
og
en
fr
ee
ze
s
an
d
de
st
ro
ys
le
si
on
s
A
pp
lie
d
di
re
ct
ly
to
le
si
on
s;
re
pe
at
fo
rt
w
o
or
th
re
e
cy
cl
es
46
–9
6
18
–3
9
•
R
ap
id
re
su
lts
in
so
m
e
pa
tie
nt
s
•
M
in
im
al
tr
ai
ni
ng
•
H
ig
h
re
cu
rr
en
ce
ra
te
•
R
ep
ea
tp
hy
si
ci
an
vi
si
ts
•
P
ai
n,
ne
cr
os
is
,
hy
po
pi
gm
en
ta
tio
n
2
0
,4
5
–
4
9
C
O
2
an
d
N
d:
Y
A
G
la
se
r
La
se
rv
ap
or
iz
es
le
si
on
s
U
nd
er
lo
ca
l
an
ae
st
he
si
a,
pr
ot
oc
ol
de
pe
nd
s
on
ty
pe
of
la
se
r
23
–9
5
2.
5–
77
•
R
ap
id
re
su
lts
•
E
ffe
ct
iv
e
fo
rt
hi
ck
le
si
on
s
•
H
ig
h
re
cu
rr
en
ce
ra
te
;i
n
so
m
e
ca
se
s
ev
en
be
fo
re
he
al
in
g
of
la
se
rt
re
at
m
en
t
•
R
ep
ea
tp
hy
si
ci
an
vi
si
ts
•
C
os
tly
•
S
ub
st
an
tia
lt
ra
in
in
g
•
E
xp
er
tis
e
re
qu
ire
d
•
P
ai
n/
sc
ar
rin
g
•
S
m
ok
e
ev
ac
ua
to
rn
ee
de
d
2
0
,4
8
,5
0
E
le
ct
ro
ca
ut
er
y
H
ig
h-
fr
eq
ue
nc
y
el
ec
tr
ic
al
cu
rr
en
ts
ca
us
e
th
er
m
al
da
m
ag
e
to
in
fe
ct
ed
tis
su
e
U
nd
er
lo
ca
l
an
ae
st
he
si
a,
ba
se
of
le
si
on
ex
ci
se
d;
re
pe
at
as
re
qu
ire
d
35
–9
4
20
–2
5
•
R
ap
id
re
su
lts
•
H
ig
h
re
cu
rr
en
ce
ra
te
•
R
ep
ea
tp
hy
si
ci
an
vi
si
ts
•
E
xp
er
tis
e
re
qu
ire
d
•
S
m
ok
e
ev
ac
ua
to
rn
ee
de
d
1
8
,2
0
,4
9
,5
1
S
ur
ge
ry
S
ci
ss
or
or
sc
al
pe
l
ex
ci
si
on
U
nd
er
lo
ca
lo
r
ge
ne
ra
la
na
es
th
es
ia
;
ba
se
of
le
si
on
ex
ci
se
d
89
–9
3
18
–6
5
•
R
ap
id
re
su
lts
•
U
se
fu
lf
or
la
rg
e
le
si
on
s
•
H
ig
h
re
cu
rr
en
ce
ra
te
•
P
ai
n/
sc
ar
rin
g
•
E
xp
er
tis
e
re
qu
ire
d
5
2
–
5
4
T
ric
hl
or
oa
ce
tic
ac
id
(3
3–
50
%
)
A
ci
d
in
du
ce
s
a
ch
em
ic
al
bu
rn
O
ne
to
th
re
e
tim
es
pe
rw
ee
k;
re
pe
at
as
ne
ce
ss
ar
y
70
–1
00
18
–3
6
•
R
ap
id
re
su
lts
•
S
ui
ta
bl
e
fo
ra
fe
w
sm
al
ll
es
io
ns
•
H
ig
h
re
cu
rr
en
ce
ra
te
•
R
ep
ea
tp
hy
si
ci
an
vi
si
ts
•
In
te
ns
e
bu
rn
in
g
se
ns
at
io
n
2
0
,4
5
,4
7
,5
5
Im
m
un
o
th
er
ap
ie
s
Im
iq
ui
m
od
5%
Im
m
un
om
od
ul
at
or
:
st
im
ul
at
es
in
te
rf
er
on
an
d
cy
to
ki
ne
pr
od
uc
tio
n
T
hr
ee
ni
gh
ts
pe
rw
ee
k
fo
r
up
to
16
w
ee
ks
or
lo
ng
er
35
–7
5
6
•
E
fﬁ
ca
cy
•
S
im
pl
e
re
gi
m
en
•
E
as
y
se
lf-
ap
pl
ic
at
io
n
•
P
re
fe
rr
ed
by
pa
tie
nt
s
•
Lo
w
er
re
cu
rr
en
ce
ra
te
s
th
an
ab
la
tiv
e
te
ch
ni
qu
es
•
In
ﬂ
am
m
at
or
y
re
ac
tio
ns
ex
te
nd
in
g
be
yo
nd
tr
ea
tm
en
t
ar
ea
ca
n
sh
ow
th
e
in
fe
ct
ed
ar
ea
•
In
ﬂ
am
m
at
or
y
re
ac
tio
ns
ex
te
nd
in
g
be
yo
nd
tr
ea
tm
en
ta
re
a
•
R
es
po
ns
e
m
ay
be
sl
ow
•
Lo
w
er
cl
ea
ra
nc
e
ra
te
s
th
an
ab
la
tiv
e
te
ch
ni
qu
es
•
R
ar
e
vi
til
ig
o-
lik
e
de
pi
gm
en
ta
tio
n
2
0
–
2
6
,4
1
,5
6
–
6
2
Im
iq
ui
m
od
3.
75
%
Im
m
un
om
od
ul
at
or
:
st
im
ul
at
es
in
te
rf
er
on
an
d
cy
to
ki
ne
pr
od
uc
tio
n
O
nc
e
da
ily
be
fo
re
be
dt
im
e
fo
ru
p
to
8
w
ee
ks
19
–3
7
15
–1
9
•
E
fﬁ
ca
cy
•
S
ho
rt
tr
ea
tm
en
td
ur
at
io
n
•
S
im
pl
e
re
gi
m
en
•
E
as
y
se
lf-
ap
pl
ic
at
io
n
•
In
ﬂ
am
m
at
or
y
re
ac
tio
ns
ex
te
nd
in
g
be
yo
nd
tr
ea
tm
en
t
ar
ea
ca
n
sh
ow
th
e
in
fe
ct
ed
ar
ea
•
In
ﬂ
am
m
at
or
y
re
ac
tio
ns
ex
te
nd
in
g
be
yo
nd
tr
ea
tm
en
ta
re
a
•
R
es
po
ns
e
m
ay
be
sl
ow
2
0
,2
7
–
2
9
© 2019 The Authors Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2019, 33, 1006–1019
Diagnosis and management of AGW 1011
T
ab
le
3
C
on
tin
ue
d
Tr
ea
tm
en
t
M
od
e
of
ac
tio
n
S
ch
ed
ul
e
C
le
ar
an
ce
ra
te
(%
)
R
ec
ur
re
nc
e
ra
te
(%
)
A
dv
an
ta
ge
s
D
is
ad
va
nt
ag
es
R
ef
s
S
in
ec
at
ec
hi
ns
10
%
an
d
15
%
In
ﬂ
am
m
at
or
y
re
sp
on
se
m
od
ul
at
or
T
hr
ee
tim
es
da
ily
fo
r
up
to
16
w
ee
ks
40
–8
1%
7–
12
•
E
fﬁ
ca
cy
•
S
el
f-
ap
pl
ic
at
io
n
•
Lo
w
er
re
cu
rr
en
ce
ra
te
s
th
an
ab
la
tiv
e
te
ch
ni
qu
es
•
In
te
ns
e
ap
pl
ic
at
io
n
si
te
re
ac
tio
ns
•
Lo
w
er
cl
ea
ra
nc
e
ra
te
s
th
an
ab
la
tiv
e
te
ch
ni
qu
es
•
R
ep
ea
t3
tim
es
da
ily
ad
m
in
is
tr
at
io
n
m
ay
af
fe
ct
ad
he
re
nc
e
•
N
ee
d
fo
rs
an
ita
ry
pa
ds
2
0
,3
0
–
3
4
O
th
er
to
p
ic
al
th
er
ap
y
P
od
op
hy
llo
to
xi
n
0.
5%
(a
lc
oh
ol
ic
so
lu
tio
n)
0.
15
%
(c
re
am
)
A
nt
im
ito
tic
ag
en
ti
nd
uc
es
tis
su
e
ne
cr
os
is
T
w
ic
e-
da
ily
to
af
fe
ct
ed
ar
ea
s
fo
r3
co
ns
ec
ut
iv
e
da
ys
pe
rw
ee
k;
di
sc
on
tin
ue
fo
r4
da
ys
;
re
pe
at
fo
ru
p
to
4
w
ee
ks
45
–9
4
11
–1
00
•
E
fﬁ
ca
cy
•
E
as
y
se
lf-
ap
pl
ic
at
io
n
•
H
ig
h
re
cu
rr
en
ce
ra
te
•
C
om
pl
ic
at
ed
re
gi
m
en
•
In
te
ns
e
ap
pl
ic
at
io
n
si
te
re
ac
tio
ns
2
0
,3
1
,3
5
–
4
0
,
4
2
–
4
4
,6
3
N
itr
ic
–z
in
c
co
m
pl
ex
to
pi
ca
ls
ol
ut
io
n
In
du
ce
s
a
ca
us
tic
ef
fe
ct
on
th
e
w
ar
t
th
ro
ug
h
m
um
m
iﬁ
ca
tio
n
an
d
pr
ot
ei
n
de
na
tu
ra
tio
n/
co
ag
ul
at
io
n
ac
tio
n
O
nc
e
or
up
to
fo
ur
tim
es
;
re
pe
at
at
2-
w
ee
k
in
te
rv
al
s
if
ne
ed
ed
90
–9
9
N
ot
ev
al
ua
te
d
•
E
fﬁ
ca
cy
•
E
as
y
ap
pl
ic
at
io
n
•
C
ur
re
nt
ev
id
en
ce
in
A
G
W
av
ai
la
bl
e
fr
om
a
lim
ite
d
nu
m
be
r
of
pa
tie
nt
s
on
ly
•
In
ve
st
ig
at
io
n
of
re
cu
rr
en
ce
ra
te
is
re
qu
ire
d
6
4
A
G
W
,a
no
ge
ni
ta
lw
ar
ts
.
© 2019 The Authors Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2019, 33, 1006–1019
1012 O’Mahony et al.
Imiquimod 5% or 3.75% Imiquimod is an immune response
modifier with antiviral activity. This Toll-like receptor 7 ago-
nist induces the production of cytokines, which enhance the
ability of antigen presenting cells to present viral antigens to
reactive T lymphocytes.21,22,65 Imiquimod 5% has been
approved for the treatment of AGW worldwide, whereas imi-
quimod 3.75% is only approved in certain countries such as
the United States of America (USA) and Canada. Imiquimod
5% is self-applied by the patient three nights per week for up
to 16 weeks; if no improvement has occurred after 4–6 weeks,
treatment can be applied daily. In comparison, imiquimod
3.75% is self-applied once-nightly for up to 8 weeks. Imiqui-
mod 5% may be applied for longer durations if there is a
good clinical result but complete clearance has not occurred at
the end of the initial treatment period.28 Both imiquimod for-
mulations are associated with local skin reactions such as ery-
thema, pruritus, burning, pain and sometimes erosions. These
are all signs that the immune system has been activated. The
lower concentration of imiquimod in the 3.75% cream is asso-
ciated with improved tolerability. In addition, the shorter
treatment duration and dosing simplicity may improve
patients’ adherence to the regimen.27 AGW clearance rates
from clinical studies range from 35 to 75% with the 5%
cream20,23,24,41,56–62 and 19 to 37% with the 3.75% formula-
tion,20,27–29 with higher clearance rates in women than men.29
Further studies have shown that patients find imiquimod 5%
to be both acceptable and preferable to other AGW treat-
ments. A study of 559 patients with AGW reported excellent,
very good or good with imiquimod 5% in 27.4%, 36.1% and
23.0% of patients, respectively.25 In addition, a survey of 629
patients showed that imiquimod 5% was rated better in terms
of overall satisfaction, convenience, time to clearance and lack
of associated pain than other AGW therapies.26
Sinecatechins Sinecatechins consist of green tea polyphenols,
which have anti-inflammatory, anti-proliferative, pro-apoptotic
and antiviral properties, although their exact mode of action
is unknown.30,31 They are available for the treatment of AGW
as a 10% and 15% ointment or cream, which is self-applied
by the patient three times per day for a maximum of
16 weeks.31 In comparison, imiquimod 5% is applied three
times weekly while application of imiquimod 3.75% is once
Figure 3 Clearance of anogenital warts with Hydrozid cryotherapy: (a) wart on prepuce; (b) hole selected from template to shield sur-
rounding tissue; (c) wart sprayed for a few seconds until frozen.
Figure 4 Clearance of anogenital warts with trichloroacetic acid: (a) application with a double-ended cotton bud to allow any trickles to
be instantly dried up; (b) rapid occurrence of frosting after application; (c) months later, no sign of warts and only slight scarring.
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daily.30 Patient adherence to dosing regimens should be con-
sidered, as compliance is important in achieving treatment
effectiveness.30 An additional factor that may affect compliance
is that sinecatechin 15% ointment is a brown formulation,67
which could stain light-coloured clothing and bedding, reduc-
ing patient adherence.
Clinical studies of sinecatechins have shown similar clearance
rates to that of imiquimod 5% therapy. Sinecatechins have
resulted in complete clearance rates of 40–81%, with comparable
differences in response rates between the 10% and 15% oint-
ments.31–34 Furthermore, the recurrence rate with sinecatechin
10% ointment was 6.8% after 12 weeks of treatment68 and 12%
with sinecatechin 10% cream following 12 weeks of treatment.32
This was higher than the recurrence rate of 6.2% observed with
imiquimod 5% treatment after 3 months and 6.3% at
6 months.62 No significant difference in clearance or recurrence
rates has been found between sinecatechin 10% cream and pla-
cebo.30 No long-term data are available for sinecatechins. The
most commonly observed application site reactions are ery-
thema, pruritus, irritation, pain and ulceration; these side-effects
may indicate the greater likelihood of a clinical response.30
Other topical therapies
Podophyllotoxin 0.15% cream or 0.5% alcoholic solu-
tion Podophyllotoxin stops division of infected cells causing
tissue necrosis.20,31,35 It can be self-applied by patients twice-
daily for three consecutive days, separated by a 4-day treatment-
free period and repeated for up to 4 weeks. Patients need to
carefully apply the solution to the lesions and avoid contact with
healthy skin. Clearance rates from clinical studies range from 45
to 94%, with common side-effects including pain, itching, burn-
ing, erosion and inflammation.20,31,35–40,42–44,63
Nitric zinc Nitric–zinc complex is a solution for topical appli-
cation containing nitric acid, zinc, copper and organic acids,
currently used to treat common warts.64 It has a caustic effect
on the wart through mummification and protein denaturation
or a coagulation action.64 The solution can be applied topi-
cally once, or up to four times, at 2-week intervals until a
complete clinical cure rate is observed.64 Clearance rates in
one study ranged from 90 to 99%, and the product was well
tolerated with no serious adverse events recorded.64 Initial
Biopsy, refer to a specialized centre or 
genotyping by PCR
>5 warts
Ablative techniques 
(if warts are still present)
2 months of immunotherapy**
A second 2-month treatment period of 
immunotherapy to treat remaining warts/
prevent recurrence
First visit
Suspected lesion
Clinical diagnosis
Recurrence
Ablative techniques 
and immunotherapy
1–5 warts
Lesions heal
Ablative techniques
Immunotherapy for 2 months to treat 
remaining warts/prevent recurrence
Anogenital warts*
Yes
No
Figure 5 A new simpliﬁed algorithm for the treatment of anogenital warts. *If large warts (too large for local TCA or cryotherapy), see Fig. 6;
**Even if some keratinized lesions are present, the goal is to treat the entire area so that non-keratinized lesions are treated with immunother-
apy followed by removal of keratinized lesions by ablative techniques. PCR, polymerase chain reaction; TCA, trichloroacetic acid
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data suggest promising efficacy in AGW; however, additional
studies are needed.
Guidance for preventing the recurrence of AGW
Anogenital warts recurrence is common and frustrating for
patients and physicians.18 Recurrence rates with conventional
ablative techniques are relatively high (Table 3), since these
methods only remove the visible wart without affecting the
underlying HPV infection.44,66 Of currently available treatments,
recurrence rates are very low with immunotherapies, imiquimod
(6–19%)20,23,28,41,56,57,60,62 and sinecatechins (4–12%),32–34 as
these treatments stimulate the host’s immune response to clear
the warts.
Studies have shown that a combination of ablative techniques
followed by immunotherapy may lead to even lower recurrence
rates; ablation provides rapid clearance but has high recurrence
rates while immunotherapy has slow clearance rates and a lower
risk of recurrence.20,69 A study of 211 patients showed that imi-
quimod 5% applied within 3 weeks after laser therapy (to ensure
complete wound healing) was associated with a low rate of wart
recurrences of 11.8% over 6 months of follow-up.69 Results of a
3-arm, open-label study involving 358 patients showed that 6-
month recurrence rates in those randomized to a combination
of ablation followed by imiquimod 5% (8%) were lower than
those after ablation alone (26%), but similar to imiquimod 5%
monotherapy (6%).62 Furthermore, the results of a retrospective
case series of 27 patients showed that combined treatment with
cryotherapy, podophyllin 25% and subsequent use of sinecate-
chins 15% ointment led to a recurrence rate of 7.4% after
6 months of follow-up.70 Gilson et al.,71 further showed that a
combination of cryotherapy and podophyllotoxin cream 0.15%
resulted in a higher clearance rate (60%) than with cryotherapy
Large warts* need surgery
Examples
Vulval and anal warts Perianal warts
First visit
• Explain need for surgery
• Prescribe imiquimod (1 box) whilst surgery is organized
• Explain imiquimod is unlikely to clear large warts but 
can create an immune response that reduces risk of 
recurrence
Surgery
Post-surgery
If lesions remain, restart imiquimod
Figure 6 A new simpliﬁed algorithm for the treatment of large
anogenital warts. *Large warts are deﬁned as too large for local
trichloroacetic acid or cryotherapy.
Figure 7 Example patient with large anogenital warts pre-treated with imiquimod before surgery: (a) vulval and anal warts in a 19-year
old who was pre-treated with imiquimod for 2 months while surgery was organized; (b) needle diathermy with smoke extractor at the start
of surgery; (b) 3 weeks post-operation, the patient remained clear of warts 9 months later.
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alone (45.7%) at both 4 and 12 weeks. However, these differ-
ences were not statistically significant.71
Pre-treatment of AGW with imiquimod to stimulate an
immune reaction followed by surgery is also associated with low
recurrence rates. A retrospective study of 60 patients with
anogenital warts showed that the recurrence rate during long-
term follow-up (up to 7 years) was lower for patients with com-
plete responses to imiquimod 5% monotherapy (15%), or with
surgical removal of residual warts after imiquimod 5% (20%),
compared with surgery alone (65%).54
A simpliﬁed algorithm for AGW treatment
A new simplified treatment algorithm for AGW is shown in
Fig. 5. Patients with a confirmed clinical diagnosis of AGW are
initially classified by their number of warts. Patients with 1–5
warts may be treated in the first instance with ablation. Once the
lesions have healed, immunotherapy can be used for 2 months
to treat remaining warts and/or prevent recurrence. The choice
of ablative technique is at the discretion of the physician taking
factors such as the location of the wart into consideration. For
those with more than five warts, the expert’s recommendation is
Table 4 Guidance for daily practice situations and the subsequent action that can be taken
Daily practice situations Actions
AGW remaining following
ablation
• Explain that residual or recurrent warts post-ablation indicate that the immune system has not been activated, which can
be more frequent in primary infections
• Initiate immunotherapy
Experience or fear of local
side-effects in genital area
• Explain how immunotherapy works
• Advise patients that local side-effects are a sign that the immune system has been activated and the therapy is work-
ing26,30,54,66,79
• With imiquimod, explain that skin reactions are common and can sometimes be associated with adverse events (head-
ache, fatigue, myalgia and nausea). Frequency of application may be reduced or treatment can be temporarily stopped if
necessary79
Limited initial efﬁcacy
with imiquimod
• Explain that some patients’ immune systems are slow to activate23,56
• Use an ablative method which can debulk and allow easier penetration
• Reassure and continue with imiquimod
• Inform the patient that some patients need the full 16-week treatment course or even longer
Lack of adherence • Determine the extent to which the patient has adhered to the treatment regimen
• Understand the reasons for lack of adherence (e.g., complicated regimen/side-effects) and ensure the patient is provided
with sufﬁcient information about AGW and the different treatments that is clear and simple, both verbally and in written
form8,75,79
• Try an alternative therapy that is associated with better adherence/improved patient satisfaction26
Lumps left may not be
true warts
• Explain (with the help of images; Fig. 2) that lumps left after treatment may not be genital warts and that they could be
large, normal glands.
Heavy cigarette smoking • Explain that smoking depresses the immune system, particularly in relation to viruses74 and it is well recognized that
smokers have more difﬁculty clearing warts and are more likely to get recurrences.16 Smoking cessation should be
encouraged
Pregnancy • Explain that pregnancy is an immune suppressed state and therefore wart infections can become large during preg-
nancy but will usually disappear within weeks of delivery76
• During pregnancy, the warts should not be treated if they do not represent an obstacle to delivery. If needed, only use
ablative methods, e.g., cryotherapy or trichloroacetic acid3,12,50
• Avoid extensive laser vaporization, electrocautery or surgery during the 6–8 weeks before delivery
• Be aware that in rare cases, HPV can be transmitted during child birth resulting in recurrent respiratory papillomatosis in
the infant73,78
Immune suppression • Establish the patient’s HIV status
• Check to see whether they are on immunosuppressive drugs for inﬂammatory bowel disease, rheumatoid arthritis etc.
Reassure the patient that clearance will still be achieved but it may take longer
Other conditions
(i.e. diabetes, eczema,
psoriasis)
• Determine if the patient has other conditions, such as diabetes, which are associated with more extensive AGW and
recurrences that may require prolonged treatment80
• More ablation and prolonged imiquimod courses may be required
• It is recommended not to use imiquimod if there is eczema, psoriasis or other dermatoses in the genital area77
Concomitant local
infections (e.g. bacterial,
fungal etc.)
• Should be treated promptly at any stage of AGW therapy
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to pre-treat the AGW with an immunotherapy for 2 months to
see whether an immune response can be stimulated. If the warts
are still present following this treatment, an ablative technique
can be used to remove the AGW. It is recommended to use a
second 2-month course of immunotherapy to treat remaining
warts and/or prevent recurrence. It is recognized that there are
many different algorithms for the treatment of AGW and that
the choice is dependent on many factors. For example, if all staff
are experienced in ablative techniques, then irrespective of the
number of warts, the clinic protocol may dictate that ablation is
used on all patients with warts at first visit, followed by
immunotherapy. In the UK, this is usual practice as it is prefer-
able for a reduced number of clinic visits.
An algorithm for the treatment of patients with large AGW is
also shown in Fig. 6. Large warts are defined as too large for
local TCA or cryotherapy, and patients with these warts should
be referred to a specialist. Based on clinical experience, our rec-
ommendation is to initially pre-treat the AGW with
immunotherapy for up to 16 weeks to stimulate an immune
reaction to reduce the risk of recurrence. In support of this,
long-term recurrence rates are lower for patients pre-treated
with imiquimod 5% followed by surgery compared with surgery
alone.54,70 Evidence for other immunotherapies in this setting is
not currently available. The AGW should then be surgically
removed under general anaesthesia, with immunotherapy being
re-started if there are residual or recurrent lesions. A histological
examination of the excised tissue should be performed to
exclude verrucous or squamous cell carcinoma. An example of a
patient treated with this approach is shown in Fig. 7.
Guidance for daily practice situations
Guidance for daily practice situations and the subsequent
action that can be taken are shown in
Table 4.3,8,12,16,23,26,30,50,54,56,62,66,72–80
Preventing AGW
Anogenital warts can now be effectively prevented using the
quadrivalent (HPV 6, 11, 16 and 18) or nanovalent (HPV 6,
11, 16, 18, 31, 33, 45, 52 and 58) HPV vaccines; these protect
against HPV types that cause AGW, cervical cancer and other
types of anogenital and oral cancer. The HPV quadrivalent
vaccine has shown to be up to 100% effective in preventing
AGW in association with vaccine-type HPV in women.81,82
After its introduction in Australia, a study with a 4-year fol-
low-up showed a 59% reduction in the prevalence of AGW in
young females.83 There was also a concomitant, although less
marked, decline in AGW in heterosexual men following intro-
duction of the vaccine.83,84 Prevention of AGW with the HPV
vaccine could therefore result in substantial savings in health-
care costs and reduction in workload for sexual health clin-
ics.85 The vaccine is also effective in 12- to 15-year-old boys
and is licensed for use in both sexes in most countries where
it is available.85,86 Evidence on whether the vaccination could
be useful in AGW treatment is not yet clear; however, there
are scientific data supporting use of the vaccination in individ-
uals previously exposed to HPV.87
Conclusions
The guidance provided will help physicians with the diagnosis
and management of AGW in daily clinical practice, in order to
improve the health and quality of life of patients with AGW. The
suggested therapeutic approach is flexible, allowing physicians to
choose treatment depending on local availability and physician
expertise, as well as considering patient preferences.
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